How do you start an optometry practice in 2027?

Direct Answer

**Starting an optometry practice in 2027 — a state-licensed eyecare clinic providing comprehensive eye exams + vision correction (spectacles + contact lenses) + ocular disease diagnosis and treatment + myopia management + dry eye disease + specialty contact lens fitting — means choosing among five business models against a fast-consolidating chain landscape, then nailing the capital + equipment + payer + optical-capture quartet.

The five models: (1) solo-OD independent (~75% of independent ODs per AOA Annual Practice Survey, 2-3 lanes, 1,800-3,500 sq ft, $550K-$1.2M gross, 22-35% net = $135K-$420K owner-OD); (2) multi-OD group (2-4 ODs, 4-8 lanes, $1.5M-$5M gross, 18-30% net); (3) affiliate-network independent (Vision Source ~3,000+ ODs at $750/mo led by Steven Eiss + Essilor-owned since 2015 / IDOC ~500 practices at ~$1,200/mo led by Dave Brown / PECAA ~1,500+ aligned ODs); (4) corporate-affiliated — sublease at LensCrafters or Pearle Vision OR W-2 employed at MyEyeDr (KKR-backed, Sue Downes CEO, ~860 offices) / National Vision NASDAQ:EYE (Reade Fahs CEO, ~1,400 stores including America's Best ~900 + Eyeglass World ~125) / Walmart Vision ~3,000+ sublease / Costco Optical ~580+ at $130-$180K base; (5) IDSO-equivalent partial-recap (EyeCare Partners Partners Group+FFL ~700+ / EyeSouth Partners Shore Capital ~300+ / Keplr Vision Greenbriar Equity ~110+ / US Eye Kuvera+Aldine ~75+ / Vision Innovation Partners Centre Lane ~80+ / Spectrum Vision Partners), selling 60-80% at 5-8x EBITDA vs traditional 0.65-0.85x collections.

The chain threat is real: EssilorLuxottica NYSE:EL (Chairman Francesco Milleri + CEO Andrea Guerra) owns LensCrafters ~840 + Pearle ~500 + Target Optical ~500 + Sunglass Hut ~3,200 + EyeMed ~70M covered lives + Essilor lens manufacturing, Warby Parker NASDAQ:WRBY (Neil Blumenthal + Dave Gilboa ~270 stores), and chain share rose from ~15% in 2010 to ~30%+ in 2024 toward 40%+ by 2030 per Review of Optometric Business.

Capital — $350K-$800K cold-start 2-3 lane OR $600K-$1.5M acquisition at 60-80% of trailing 12-mo collections — funded via SBA 7(a) through Live Oak Bank Eyecare, Bank of America Practice Solutions, First Citizens Practice Solutions, Provide.com (was Lendeavor), Huntington Practice Finance, or US Bank Practice Finance.

Exam-lane equipment fundamentals at $15-$25K/lane: Marco TRS-3100/5100/6100 chair-stand + Reichert Ultramatic phoropter $4-$18K + Haag-Streit BQ-900 slit lamp gold $4-$15K + Nidek/Topcon auto-refractor $7-$15K + NCT $3-$8K. Diagnostic imaging (the medical-OD enablers): Canon CR-2 retinal camera $25-$40K OR Optos California ultra-widefield 200° $90-$130K + Heidelberg Spectralis OCT $60-$80K gold standard OR Topcon Maestro2 / Zeiss Cirrus 6000 + corneal topographer Medmont E300 / Eaglet ESP / Oculus Pentacam $25-$45K + HFA3 visual field $22-$30K + Zeiss IOLMaster 700 axial length biometer $55-$70K (CRITICAL for myopia management).

Optical lab: Essilor Independent Labs (Varilux + Crizal + Transitions + Stellest myopia) + Walman Optical employee-owned + Hoya Vision (MiYOSMART myopia + Recharge AR) + Younger Optics (Drivewear + NuPolar) + Shamir Insight (Autograph III + Glacier+ AR).

PMS at $300-$1,500/mo: Compulink Advantage + RevolutionEHR cloud OD-specific fastest-growing + Crystal PM + Eyefinity OfficeMate (VSP-owned, deep VSP integration) + Maximeyes / Acuity Logic / Uprise.

Operations: hiring associate OD $130-$170K + opticians $22-$35/hr + techs $18-$26/hr; vision insurance vs medical billing workflow (VSP ~80M Mike Hamlin CEO + ~30% US vision insurance share / EyeMed ~70M Lukas Ruecker CEO EssilorLuxottica-owned / Spectera ~25M UHG / Davis Vision/MetLife ~20M / Versant Health Superior+Davis) compresses optical margin 40-60%, vs medical-OD 99213-99215 ($75-$170) + 92133 RNFL $45 + 92134 macular $45 + 92250 fundus $50 + G0117 diabetic $53 at 2-3x reimbursement.

The S-T-O-P optical sale workflow (Select frame → Talk lens tech → Offer treatments AR/blue/photochromic → Position pricing) drives the top-vs-bottom delta — top quartile closes 70-85%, bottom 35-45%. Contact lens annual supply 75-90% conversion: Acuvue Oasys 1-Day HydraLuxe (Johnson & Johnson Vision) / Alcon DAILIES TOTAL1 + Precision1 + Air Optix HydraGlyde / CooperVision MyDay + Biofinity / Bausch + Lomb Biotrue ONEday + INFUSE + Ultra.

The four 2027 revenue moats independents counter chains with: (A) myopia management $4-$6B emerging specialty 25-40%/yr — CooperVision MiSight 1-day FDA + Essilor Stellest CE-mark + Hoya MiYOSMART + Visioneering NaturalVue Multifocal + Paragon CRT/Wave/Euclid ortho-k + atropine 0.05% compounded via Imprimis/Leiter's at $1,500-$3,500/yr/pediatric packages; (B) dry eye disease center $300-$3,000 protocols outside vision insurance — TearLab osmolarity + Lumenis OptiLight M22 IPL $75-$110K FDA + J&J LipiFlow + NULIDS + Restasis (AbbVie) / Cequa (Sun Pharma) / Xiidra / Tyrvaya (Viatris) / Miebo (Bausch + Lomb); (C) specialty contact lens — sclerals $1,200-$3,500 (BostonSight / Valley Contax / X-Cel Specialty / Visionary Optics) + ortho-k $1,500-$3,500; (D) medical-OD transition away from vision-plan reliance toward 99213-99215 medical CPT billing.

Compliance non-negotiables: state OD board + DEA + state therapeutic/laser (TPA scope varies; OK+LA+KY+AK+VA grant laser SLT/YAG/LPI) + NPI + HIPAA + OSHA Bloodborne Pathogens + FTC Eyeglass Rule (Rx released after refraction no charge) + FTC Contact Lens Rule (CL Rx + 1-yr verification) + state optician licensure (~22 states).

AI imaging FDA-cleared add-ons $300-$2,000/mo: Eyenuk EyeArt diabetic retinopathy + Notal Vision ForeseeHome AMD + RetinAI multi-pathology OCT + AEYE Health autonomous DR.

The hardest part is NOT capital or OCT/topographer spend — it is the trifecta of (1) optical capture via S-T-O-P (55-70% of independent OD gross), (2) VSP/EyeMed write-off management + medical-OD billing transition, and (3) chain/corporate positioning via myopia + dry eye + specialty CL + medical-OD moats.

Benchmark sources: American Optometric Association (AOA), Review of Optometric Business, Vision Council, BLS Occupational Outlook 2024 — Optometrists, ASCO, ARBO, NBEO, American Academy of Optometry, Brien Holden Vision Institute, and International Myopia Institute for the myopia management consensus that grounds the $4-$6B emerging-specialty thesis.**

Table of Contents

Part 1 -- Foundations

• Market size, OD supply, optical retail landscape
• Four practice archetypes
• OD pathway, NBEO, TPA scope
• Chain consolidation + medical-OD shift

Part 2 -- Build-Out & Capital

• Real estate + exam lane build-out
• Exam-lane equipment + diagnostic imaging
• Optical lab + frame inventory
• PMS + AI imaging + supplies
• SBA + eyecare-specific financing

Part 3 -- Operations

• Hiring (associate OD + opticians + techs)
• Vision insurance vs medical billing workflow
• S-T-O-P optical sale workflow
• Contact lens + specialty CL revenue
• Myopia management revenue lever
• Dry eye disease center model
• Compliance: HIPAA + OSHA + FTC + optician licensure

Part 4 -- Growth & Exit

• Marketing realities
• Scale model + IDSO-equivalent landscape
• Vision Source/IDOC/PECAA affiliate routes
• Exit options
• Chain threat + independent moats

PART 1 -- FOUNDATIONS

1. Market size, OD supply & the optical retail landscape

US optical retail generates ~$50B annual revenue (Vision Council 2024) -- spectacle lenses ~$22B + frames ~$15B + contact lenses ~$8B + sunwear ~$5B -- across ~40K independent optometry practices + ~9,000 chain/corporate locations + ~46K active ODs (AOA + BLS 2024). The defining 2024-2027 macro: chain consolidation accelerating (chain ODs grew from ~15% in 2010 to ~30%+ in 2024 per Review of Optometric Business, projected 40%+ by 2030) + the myopia management revolution (FDA approval of CooperVision MiSight 1-day 2019 + Essilor Stellest CE-mark + ortho-k mainstreaming + atropine 0.05% compounded).

Quick Facts

• ~$50B US optical retail (Vision Council 2024)
• ~46K active optometrists (AOA + BLS 2024)
• ~40K independent optometry practices
• ~9,000 chain/corporate eyecare locations
• ~75% of independent ODs in solo or 2-doc (AOA, trending corporate)
• ~$650-$900K avg solo OD gross collections
• $135-$220K owner-OD net (top quartile $280-$450K)
• VSP ~80M / EyeMed ~70M / Spectera ~25M / Davis ~20M covered lives
• ~30% chain market share 2024, 40%+ projected 2030

The chain landscape. EssilorLuxottica (Francesco Milleri Chairman, Andrea Guerra CEO) owns LensCrafters ~840 + Pearle Vision ~500 + Target Optical ~500 + Sunglass Hut ~3,200 = ~$5B+ US optical retail + EyeMed (~70M covered lives) + Essilor lens manufacturing + Ray-Ban/Oakley/Persol/Oliver Peoples frame brands.

National Vision (NASDAQ:EYE, Reade Fahs CEO, ~1,400 stores) operates America's Best Contacts & Eyeglasses ~900 + Eyeglass World ~125 + Walmart Vision sublease + Fred Meyer Optical. MyEyeDr (KKR-backed since 2019, Sue Downes CEO, ~860 offices) -- fastest-growing roll-up of independent practices.

Walmart Vision Centers ~3,000+ stores sublease ODs. Costco Optical ~580+ employed ODs $130-$180K. Warby Parker (NASDAQ:WRBY, Neil Blumenthal + Dave Gilboa, ~270 stores + ecommerce).

Vision Source / IDOC / PECAA. Vision Source (Steven Eiss former CEO, Essilor-owned since 2015) -- ~3,000+ affiliated ODs, $750/mo + buying-group rebates + consulting. IDOC (Dave Brown CEO, ~500 practices) -- heavier consulting + financial benchmarking + ~$1,200/mo. PECAA -- ~1,500+ aligned ODs, buying group + insurance leverage.

Education-debt + DSO-acceptance flywheel. OD-school debt averages $185K-$305K at graduation per ASCO 2024. New grads accept MyEyeDr/National Vision/Walmart/Costco employment at $130K-$170K starting + bonus because immediate cashflow services debt -- driving chain market share from ~15% in 2010 to ~30% in 2024 to projected 40%+ by 2030.

Demand fundamentals + myopia surge. 65+ population: ~58M in 2024 -> ~78M by 2035 (US Census), creating chronic-disease OD opportunity. Childhood myopia prevalence: ~25% in US 2024, projected ~50% by 2050 globally per Brien Holden Vision Institute -- driving the $4-$6B emerging myopia management specialty.

2. Four practice archetypes

The single most consequential 2027 decision is archetype selection -- it dictates capital intensity, payer mix, exit multiple, lifestyle.

Solo-OD independent. 1 owner-OD + 1-2 opticians + 1-2 techs + 1 front office. 2-3 lanes, 1,800-3,500 sq ft, $550K-$1.2M gross, 22-35% net = $135K-$420K. Most exposed to chain competition + VSP/EyeMed compression. Top quartile $1.2M-$2.5M with strong S-T-O-P + medical-OD billing + myopia buildout.

Multi-OD group. 2-4 ODs + 3-5 opticians + 3-5 techs + 2-3 front office. 4-8 lanes, 3,500-7,000 sq ft, $1.5M-$5M, 18-30% net = $270K-$1.5M. Operating leverage from shared optical + diagnostic equipment + insurance contracts. Common path to IDSO-equivalent.

Affiliate-network independent. Preserves branding + clinical autonomy + ownership + adds Vision Source ($750/mo)/IDOC ($1,200/mo)/PECAA buying-group rebates (Essilor lens 8-15% + frame co-op + CL manufacturer rebates) + practice consulting + insurance contract leverage.

Corporate-affiliated / employed. (a) Sublease at LensCrafters/Pearle/Target -- OD pays $3-$8K/mo rent + collects exam fees + production bonus; host owns optical. (b) Employed at MyEyeDr/National Vision/Walmart/Costco -- W-2 at $130-$180K base + bonus + benefits + zero ownership risk. Best for new-grads servicing OD school debt.

3. OD pathway, NBEO, state licensure & TPA scope

Clinical pathway: 4-yr undergraduate + OAT + 4-yr optometry school at one of ~23 ACOE-accredited schools (Berkeley, SUNY College of Optometry, UAB, Indiana, Houston, Ohio State, Pacific U, Salus, Illinois College, MBKU, Nova Southeastern, NEOMED, etc.) earning OD. Then NBEO Part I + Part II + Part III.

Then state board license + jurisprudence. Many ODs add a 1-yr residency in ocular disease / cornea / pediatrics / low vision.

DEA registration for therapeutic/oral prescribing (oral antibiotics, oral steroids, oral antivirals). NPI for insurance billing. Medicaid optional.

TPA scope varies dramatically. All 50 states grant some therapeutic authority but scope varies -- Oklahoma + Louisiana + Kentucky + Alaska + Virginia grant the broadest including laser procedures (YAG capsulotomy, SLT, LPI). Most states grant topical + oral medication but reserve injections + laser to ophthalmology.

CA + MA + NY + TX more restrictive. Check state board scope-of-practice -- drives chronic-disease billing potential.

Continuing Education. State boards require 18-50 CE hours per renewal cycle, 50%+ COPE-accredited. Major providers: AOA Optometry's Meeting, Vision Expo East NYC March + West Vegas September, SECO Atlanta March, AAO Academy, Review of Optometry CE Online.

4. Chain consolidation reality & the medical-OD shift

EssilorLuxottica owns ~$5B+ US optical retail + EyeMed (~70M lives, captive vision-insurance arm) + Essilor lens manufacturing + most major frame brands. MyEyeDr (KKR, ~860 offices) -- the fastest-growing roll-up; typically buys 60-80% equity + retains OD as clinical lead + retains branding initially + converts over 2-5 yrs + centralizes back-office.

National Vision (NASDAQ:EYE, ~1,400 stores) -- low-cost model exam + 2 pairs $79.95.

The IDSO-equivalent in eyecare -- fastest-growing 2024-2027. Vision Innovation Partners (Centre Lane Partners) -- preserves practice branding + clinical autonomy + employees while centralizing insurance contracting, HR, marketing, supply. US Eye (Kuvera + Aldine Capital, ~75+) -- OD + MD combined.

EyeCare Partners (Partners Group + FFL Partners, ~700+ locations) -- largest combined OD + MD platform. Keplr Vision (Greenbriar Equity, ~110+) -- independent-friendly retaining branding. EyeSouth Partners (Shore Capital, ~300+, ophthalmology-heavy).

Spectrum Vision Partners (PE-backed Northeast). Typical deal: 60-80% equity at 5-8x EBITDA + clinical autonomy + 20-40% retained equity + second-bite at next recap in 3-7 years (2-3x return on retained).

The medical-OD shift -- the strategic moat. Independent ODs increasingly bill medical insurance (BCBS/Aetna/Cigna/UHC/Medicare) at 2-3x vision-plan reimbursement by managing chronic ocular disease: diabetic eye exam G0117 ($53 Medicare) + glaucoma 92083 visual field + 92250 fundus photography + dry eye + neuro-optometry post-concussion + neurolens prism.

A patient w/ "red eye, headaches, floaters, blur with diabetes" bills medical 99213-99215 ($75-$170) + ancillary tests, NOT vision 92002/92004/92012/92014 ($45-$95). Heavy-medical practices net 35-50% vs heavy-vision-plan 18-28%.

PART 2 -- BUILD-OUT & CAPITAL

1. Real estate & exam lane build-out

Quick Facts

• 2-lane startup: $250-$500K (1,200-2,000 sq ft)
• 3-lane independent: $350-$800K (1,800-3,500 sq ft)
• 4-lane full-diagnostic: $700K-$1.5M (3,000-5,000 sq ft)
• Acquisition: $600K-$1.5M at 60-80% trailing 12-mo collections
• TI build-out: $200-$350/sq ft
• Exam-lane equipment: $35-$75K per lane
• Frame inventory opening: $30-$80K (300-800 frames at 3x markup)

Site selection. Want 2-3 mile residential density 25K+ households + median HHI $60K+ + visible signage + 15-25 parking spots + co-tenant traffic (grocery/pharmacy/pediatric). Demographic match to focus: myopia mgmt near schools/young families, dry eye + medical-OD near 45+ retirees.

Avoid heavy chain saturation -- if LensCrafters + America's Best + MyEyeDr + Walmart Vision within 2 miles, exam capture 2-3x harder.

Exam lane layout & MEP. OD build-out runs $200-$350/sq ft TI -- medical-grade plumbing at exam lanes + medical-grade electrical (chair-stand 20A dedicated) + HIPAA-compliant front office + ADA-accessible lanes + pre-test room with auto-refractor + NCT + retinal camera + dilation/wait area + optical retail floor + CL dispensing + optional lab room.

Build-out timeline runs 6-10 months lease-to-first-patient: 30-60 day design + permitting + 90-120 day construction + 30-60 day equipment install + insurance credentialing + training.

Lease vs buy. Lease $2,000-$5,500/mo per 1,000 sq ft suburban, $4,000-$9,000 metro. Many OD owners buy real estate via separate LLC + lease to PC.

2. Exam-lane equipment fundamentals

Chair-stand + delivery + slit lamp + lighting. $15-$25K per lane new (Marco/Reichert/Reichelt TRS-3100/5100/6100 gold standard; Topcon CV-5000; Nidek RT-6100). Refurb $7-$15K saves $8-$15K/lane.

Phoropter. $4-$12K manual (Reichert Ultramatic RX, Marco RT-700, Topcon VT-10) vs $8-$18K digital integrated (Marco TRS-5100, Topcon CV-5000PRO, Nidek RT-6100, Visionix VX55).

Slit lamp. $4-$12K (Haag-Streit BQ-900 gold at $10-$15K, Topcon SL-D $5-$10K, Marco/Reichert $4-$8K). Add digital imaging module $3-$8K for anterior segment photography + dry eye documentation.

Auto-refractor + keratometer. $7-$15K (Nidek ARK-1s, Topcon KR-800, Marco Equip ARK-510A, Reichert RK-700, Visionix VX120).

Non-contact tonometer. $3-$8K (Reichert 7CR, Topcon CT-1, Nidek NT-510). Or iCare TA01i rebound $2-$4K (handheld, pediatric-friendly).

3. Diagnostic imaging (the medical-OD enablers)

Retinal camera. $25-$130K range. Canon CR-2 $25-$40K entry non-mydriatic. Topcon TRC-NW8 $35-$55K. Optos California $90-$130K (ultra-widefield 200deg single capture, no dilation -- dominant upgrade, drives medical billing 92250 fundus photo ~$50 Medicare).

OCT. $40-$80K. Heidelberg Spectralis $60-$80K (gold standard, multimodal). Topcon Maestro2 $40-$55K.

Zeiss Cirrus 6000 $45-$70K. Optovue iVue 80 $35-$50K. AI-augmented analysis (Notal Vision, RetinAI, Eyenuk) flags AMD + DR + glaucoma RNFL thinning.

Highest-ROI medical-OD investment -- 92133 RNFL OCT ($45) + 92134 macular ($45).

Corneal topographer. $25-$45K. Medmont E300 $30-$45K (ortho-k + RGP fitting gold). Eaglet Eye ESP $25-$40K (scleral fitting). Oculus Pentacam $35-$55K (keratoconus + LASIK referral). Essential for myopia management ortho-k + specialty CL fitting.

Visual field. $20-$30K. Zeiss Humphrey HFA3 $22-$30K (gold standard, SITA Faster). Octopus 900 $25-$35K. Drives glaucoma billing 92083 ($60-$80).

Axial length biometer. $45-$70K. Zeiss IOLMaster 700 $55-$70K (gold, swept-source). Topcon Aladdin $35-$50K. Tomey OA-2000 $40-$55K. CRITICAL for myopia management -- axial length is the only direct measure of myopia progression + pathology risk. 2027 myopia protocol REQUIRES axial length every 6 months per IMI consensus.

4. Optical lab + frame inventory

Lab partnership. Most ODs outsource: Essilor Independent Labs (owns Varilux, Crizal, Transitions, Eyezen, Stellest), Walman Optical (employee-owned), IcareLabs, Hoya Vision Care, Younger Optics (Drivewear/NuPolar), Shamir Insight (Glacier+). Lab does surfacing + tinting + coating + edging + mounting; ships in 5-10 business days.

In-house edging (optional). $25-$60K finishing edger (Briot Accura, Santinelli LE-1200, Essilor Mr Blue) enables same-day stock-lens glasses. ROI debatable sub-$1.5M.

Frame inventory opening. $30-$80K for 300-800 frames. Margin: 3x retail markup standard. Mid-market designer (Coach, MK, Burberry, Calvin Klein -- via Marchon/Safilo/Luxottica) $80-$140 cost / $240-$420 retail.

Premium (Tom Ford, Gucci, Prada -- Luxottica/Kering) $150-$280 cost / $450-$840. Independent boutique (Etnia Barcelona, Lafont, Anne et Valentin, Salt, Garrett Leight, Moscot, Lindberg) $130-$320 cost / $390-$960. Kids (Dilli Dalli, OGI) $40-$90 cost / $120-$270 for myopia volume.

CL inventory. 200-500 trial SKUs from CooperVision (MiSight, Biofinity, MyDay), J&J Vision (Acuvue Oasys 1-Day, Vita, Moist), Alcon (DAILIES TOTAL1, Air Optix), Bausch + Lomb (INFUSE, Biotrue, Ultra), specialty (X-Cel, Valley Contax, BostonSight SCLERAL). Direct-ship annual supply w/ rebates $75-$200/yr/patient.

5. PMS + AI imaging + supplies

PMS. $300-$1,500/mo: Compulink Advantage (legacy + cloud, broad OD-specific), RevolutionEHR (cloud, fastest-growing independent), Crystal PM, Eyefinity OfficeMate + ExamWriter (VSP-owned, deep VSP integration), Maximeyes by NextGen, My Vision Express, Acuity Logic (chain sublease), Uprise (VSP/Eyefinity newer cloud).

Patient comms + recall. Weave (PMS-integrated text + voice + reviews + payments, fastest-growing), Solutionreach (legacy), NexHealth, Doctible, 4Patient Care.

AI fundus/OCT analysis (NEW 2024-2027). $300-$2,000/mo: Eyenuk (FDA-cleared diabetic retinopathy), Notal Vision (AMD home monitoring), RetinAI (multi-pathology OCT), AEYE Health (FDA autonomous DR), Optomed Aurora AEYE (handheld + AI).

Supplies. Three dominant ophthalmic distributors: Lombart Instruments, Marco Ophthalmic, Veatch Ophthalmic. Frame distribution direct from Luxottica, Safilo, Marchon, Marcolin, Kering Eyewear, ClearVision Optical, Modern Optical. Annual consumables 3-lane practice $25-$55K.

6. SBA + eyecare-specific financing

Eyecare has built the second-strongest specialty-finance ecosystem after dental -- sub-2% historical default rate.

Typical 3-lane de novo 2026: lease $0 + TI $500-$875K + lane equipment $105-$225K + retinal camera + OCT + topographer + visual field + biometer $180-$355K + frame inventory $30-$80K + IT/PMS/signage $25-$45K + working capital $80-$200K = $350-$800K de novo or $600K-$1.5M (real estate purchase).

Acquisition financing: $400K-$1.2M (60-80% trailing collections) + 10-20% down + SBA 7(a) 75-90% + seller note 5-15% at 6-8% 5-7 yr + working capital reserve $40-$120K.

Eyecare-specific lenders: Live Oak Bank Eyecare Lending (top SBA), Bank of America Practice Solutions (largest non-SBA), First Citizens Practice Solutions (was Square 1), Provide.com (was Lendeavor, expanded to eyecare 2022), Huntington Practice Finance, US Bank Practice Finance, TD Bank Healthcare.

Equipment leasing: Marco Financial, Topcon Financial, US Bank Equipment Finance, Western Equipment Finance, Essilor Instruments.

PART 3 -- OPERATIONS

1. Hiring

Associate OD. $130-$170K starting new-grad (BLS 2024 + AOA Career Survey). $160-$220K experienced 5+ yr + production bonus 18-22%. Highest-paying: Costco $150-$200K + benefits, MyEyeDr $140-$180K + production, large groups $150-$220K + partnership track.

Optician. $42-$60K licensed (~22 states require optician licensure -- CA/FL/NY/NJ/CT/MA/RI/HI/GA/KY/MD/etc.). ABO + NCLE certifications optional but increasingly required -- adds $3-$6/hr premium. Top opticians closing 70-85% optical capture earn $55-$85K + commission.

THE most important non-OD hire -- drives 55-70% of practice gross.

Optometric technician. $18-$28/hr for pre-test + chair-side + diagnostic equipment operation. ABO/NCLE Optical Technician cert $0.50-$2/hr premium.

Optical sales. $16-$24/hr base + commission ($35-$50K base + $5-$25K commission). Commission: 4-8% of net optical sales OR tiered. Separate from licensed optician role -- handles frame selection + lens upgrade + insurance breakdown + financing + 2nd-pair offers. Best drive 30-50% revenue lift over untrained.

Front office. $16-$22/hr + insurance verification + scheduling + recall + collections. 2-4 per 3-4 lane practice. Outsource RCM optional (RevSync, Insight Practice Partners).

2. Vision insurance vs medical billing workflow

The single most consequential financial decision is payer mix -- which vision plans + medical insurance to credential with + how aggressively to bill medical.

Four major vision plans (each 60-120 day credentialing): VSP Vision Care (~80M lives, dominant US vision insurance -- owns Eyefinity OfficeMate + Marchon frames; ~30% market share). EyeMed (~70M, EssilorLuxottica-owned, ties to LensCrafters/Pearle/Target chains, often lowest-paying for independents).

Spectera / UnitedHealthcare Vision (~25M, UHG-owned). Davis Vision / MetLife (~20M). Plus Versant (Superior), NVA, March Vision (Medicaid).

Vision plan write-off math. Allowed amounts write off 40-60% of UCR. Example: UCR progressive + premium AR $480; VSP Choice allowed $230 + member copay $60 = $290 reimbursement = 40% write-off. Frame UCR $300; VSP allowance $130 + 20% over-allowance copay = $164 = 45% write-off.

Heavy vision-plan 18-28% net; light + medical-heavy 35-50%; FFS/concierge 40-55%.

The medical-OD billing transition. Vision codes 92002/92004/92012/92014 ($45-$95) bill under vision plans. Medical codes 99213/99214/99215 ($75-$170) bill under BCBS/Aetna/Cigna/UHC/Medicare with medical chief complaint -- "red eye, foreign body, blur with diabetes, headaches, sudden floaters, ptosis, double vision, dry eye".

Add ancillaries: 92133 RNFL OCT ($45), 92134 macular OCT ($45), 92250 fundus photo ($50), 92083 visual field ($60-$80), 92020 gonioscopy ($25), 92015 refraction (patient-pay $50-$80 if non-covered). Diabetic eye exam G0117 ($53 Medicare) is bread-and-butter.

3. The S-T-O-P optical sale workflow

Optical capture is the optometry version of dental case acceptance. Patient finishes exam w/ Rx; optician has 5-15 min to convert to frame + lens + AR + photochromic + 2nd-pair before patient leaves to LensCrafters/Costco/Warby Parker/1-800-CONTACTS/EyeBuyDirect/Zenni. Top closes 70-85%; bottom 35-45%. 30-50 point gap = difference between $650K and $1.4M practice on same OD-hours.

Key Stat

Per Review of Optometric Business + Vision Source + IDOC benchmarks, top decile reports optical capture 75-85% vs bottom quartile 30-40%; gap driven by S-T-O-P workflow: (S)elect frame based on face shape + lifestyle + Rx, (T)alk lens tech (high-index 1.67/1.74 thin Rx, polycarbonate kids/sports, Trivex rimless, occupational progressives), (O)ffer treatments (premium AR Crizal Sapphire/Sapphire HR, blue-blocker, photochromic Transitions Gen 8 / Drivewear), (P)osition pricing (insurance + financing CareCredit/Sunbit + 2nd-pair + annual CL supply).

Bottom hands patient paper Rx + sticker.

4. Contact lens revenue + specialty CLs

CL annual supply is the recurring-revenue analog. Top practices convert 75-90% to annual supply (12-mo bulk + manufacturer rebate $75-$200 + direct-ship + auto-reorder). Daily disposables dominate -- Acuvue Oasys 1-Day with HydraLuxe (J&J, premium daily), DAILIES TOTAL1 (Alcon, water-gradient), MyDay (CooperVision, silicone hydrogel daily), Biotrue ONEday (B+L).

Monthly silicone hydrogels -- Acuvue Vita, Air Optix HydraGlyde, Biofinity, Ultra.

Specialty CLs (the differentiation moat). Sclerals ($1,200-$3,500 fit + $400-$900 replacement) for keratoconus, post-LASIK ectasia, severe dry eye. Labs: BostonSight SCLERAL, Valley Contax, X-Cel Specialty, Visionary Optics, Essilor Custom Stable. Multifocal CLs (DAILIES TOTAL1 Multifocal, Ultra Multifocal, Biotrue) $80-$140 fit.

Ortho-K ($1,500-$3,500 fit + $600-$1,200/yr replacement) -- Paragon CRT (CooperVision), Wave, Euclid Emerald.

5. The myopia management revenue lever

Key Stat

Per CooperVision MiSight data + Brien Holden Vision Institute + International Myopia Institute + Review of Optometric Business: childhood myopia prevalence ~25% in US 2024, projected ~50% globally by 2050; high myopia (>-6.00) carries 5-10x lifetime risk of myopic maculopathy + retinal detachment + open-angle glaucoma per IMI consensus.

Myopia management is a $4-$6B emerging specialty growing 25-40%/yr with FDA-approved CooperVision MiSight 1-day (only FDA-approved myopia control CL) + Essilor Stellest + Hoya MiYOSMART + Visioneering NaturalVue Multifocal + ortho-k + atropine 0.05% (Imprimis/Leiter's). Top myopia practices package $1,500-$3,500/yr per pediatric patient + 6-mo follow-up + axial length (IOLMaster 700) + parent education.

6. Dry eye disease center model

DED is the strategic patient-acquisition front door + a $300-$3,000/protocol revenue stream OUTSIDE vision insurance. Estimated 16-49M US adults suffer DED.

Diagnostics: TearLab Osmolarity ($35-$60 patient-pay, gold), InflammaDry (MMP-9 $30-$50), LipiScan/LipiView (J&J Vision meibography $50-$100), Schirmer test (basic), Oculus Keratograph 5M ($25-$45K tear meniscus + NIBUT + meibography all-in-one).

Treatment: IPL (Intense Pulsed Light) Lumenis OptiLight M22 ($75-$110K capital + $250-$400/session x 4-session = $1,000-$1,600/course). LipiFlow thermal pulsation (J&J, $80-$120K + $700-$1,200/treatment). iLux / TearCare (lower-capital).

NULIDS at-home $200-$400. OmegaScan/EyePromise nutraceutical omega-3. Rx pharmacotherapy (Restasis, Cequa, Xiidra, Tyrvaya, Miebo, Eysuvis -- bill medical w/ prior auth).

7. Compliance: HIPAA + OSHA + state board + FTC + optician licensure

Warning

HIPAA breach + state board complaint + dispensing without licensed optician (licensure states) + FTC Rx withholding = automatic civil penalty + potential license suspension.

HIPAA + HITECH -- annual Risk Assessment, BAAs every vendor (PMS, AI imaging, billing, IT, texting), encrypted email/storage, 60-day breach notification. Civil penalty $100-$50K per record (capped $1.5M/yr per category).

OSHA + Bloodborne. Disinfection of slit lamp + tonometer tip + trial lens + after dilation + IPL eye-safety. Annual training + sharps log.

State OD board + CE. Standard-of-care (missed glaucoma/retinal detachment/melanoma), billing fraud (G0117/fundus photo without indication), advertising, prescription release. CE renewal current.

Optician licensure in ~22 states (CA/FL/NY/NJ/CT/MA/etc.). Practice must employ licensed opticians OR OD personally dispenses. ABO + NCLE voluntary nationwide.

FTC Eyeglass Rule + Contact Lens Rule. Federal rule -- glasses Rx released to patient no charge after refraction. CL Rx released after fitting + verified 1 year. Cannot condition Rx release on optical purchase. Violation = FTC enforcement.

PART 4 -- GROWTH & EXIT

1. Marketing realities

Dominant 2027 OD channels: Google + Google Business Profile + Google Reviews + Healthgrades + ZocDoc + Facebook for myopia-management parent-targeted + postcard mail for new movers + dry eye as front door.

Reviews. Goal: 4.7+ stars x 100+ Google reviews. Asked at checkout via Weave/Solutionreach/NexHealth/Doctible. Negative response within 24 hrs, no PHI disclosure.

Healthgrades + ZocDoc drive 25-40% of new-patient appointments at urban/suburban practices. ZocDoc charges $40-$110/booked new patient.

Dry eye marketing as front door. Top-decile practices market DED screening as patient acquisition wedge -- converts to comprehensive exam + medical billing + IPL/LipiFlow packages.

Facebook for myopia management. Parent-targeted (4-12 yo children, parent age 30-50, HHI $75K+) for MiSight/Stellest/ortho-k. CAC $200-$500/child; LTV $4,000-$8,000/4-yr course.

Patient referrals = #1 acquisition channel mature -- 30-45% of new-patient volume. Refer-a-friend $25-$50 + experience excellence + automated review-request.

2. Scale model

Yr 0-3 solo $550K-$1.2M 22-35% net -> Yr 3-7 2-OD or 2nd location $1.5-$3M 18-30% -> Yr 7-12 multi-location 3-5 $3-$10M 16-26% -> Yr 12-20 regional 6-15 $10-$40M 14-22% -> Yr 20+ platform 15-100+ $30M-$500M+ -> IDSO exit.

Second-location decision triggers at 85%+ chair-time + strong associate-OD ready as managing doctor OR attractive adjacent acquisition. Stage 1->2 stall solved by clear associate-to-partner pathway OR IDSO-equivalent funding 2nd location.

3. IDSO-equivalent landscape

Key Stat

Per Vision Monday + Review of Optometric Business + Provident Healthcare Partners eyecare M&A: eyecare IDSO partial-recap multiples 2024-2026 run 5-8x EBITDA for $250-$750K EBITDA, 6-9x for $750K-$1.5M EBITDA groups, 8-12x for $1.5M+ platforms. Owner sells 60-80% equity + retains 20-40% rolled into platform equity + second-bite at next recap in 3-7 yrs typically returns 2-3x on retained.

Multiples expanded 1-2 turns 2020-2024 as IDSO competition intensified.

Deal structure typical. $1.2M collections + $300K EBITDA -> 6.5x EBITDA = $1.95M EV + IDSO buys 70% = $1.36M cash + owner retains 30% = $585K + 3-5 yr contract + clinical autonomy + branding. At next recap (3-5 yr) platform sells at 9-12x EBITDA = retained worth $1.0-$1.7M = 2-3x = total to owner $2.4-$3.1M vs traditional sale 0.65-0.85x collections = $780K-$1.0M one-time.

Best M&A advisory: Provident Healthcare Partners (eyecare-specific), Vision Monday Group, Cain Brothers, ROI Corp (was Edgewood), Eyecare Practice Transitions, Williams Group, Practice Concepts.

4. Vision Source / IDOC / PECAA affiliate routes

Vision Source (Essilor-owned since 2015, ~3,000+ ODs, $750/mo) -- buying group + Essilor lens 8-15% rebate + frame co-op + CL rebates + consulting. IDOC (~500 affiliates, ~$1,200/mo, Dave Brown CEO) -- heavier consulting + financial benchmarking + IDOC Connection conference.

PECAA (~1,500+ aligned ODs) -- buying group + insurance leverage. Best for ODs who want to stay independent forever but capture chain-scale buying economics.

5. Exit options

(1) IDSO-equivalent partial-recap. Sell 60-80% to EyeCare Partners/MyEyeDr/Keplr/US Eye/VIP/Spectrum at 5-8x EBITDA + retain 20-40% + clinical autonomy + 3-5 yr contract + second-bite. Best for ODs 5-15 yrs from retirement seeking partial liquidity + reduced ops burden.

(2) Traditional sale to single buyer. Sell to another OD (often new-grad with SBA + eyecare-specific lender) at 60-80% of trailing 12-mo collections + working capital. Broker (Provident/ROI Corp/Eyecare Practice Transitions/Williams/Practice Concepts) + 6-18 mo timeline + seller note 5-15%.

PacNW/Bay/NYC premium 75-90%; rural Midwest 50-65%.

(3) Merge with peer. Two adjacent solo ODs merge into 2-OD group sharing facility + equipment + insurance.

(4) Associate-to-partner buyout. Owner sells to long-time associate over 3-5 yr staged. Yr 1-2 associate buys 20-30% at 75-80% of collections-based valuation.

(5) Lifestyle-OD / multi-generational independent. Stay 1-OD or 2-OD at $700K-$1.5M, take home $180-$320K, work 32-38 hrs/week. Dominant choice for ~50-60% of independent ODs per AOA.

6. The chain threat + independent moats

Chains compete on price + insurance volume + convenience. Independents counter with clinical depth + relationships + specialty:

• Myopia management -- chains rarely build (requires biometer + topo + dedicated CE + parent consultation)
• Dry eye disease center -- chains don't invest in $200-$310K IPL/LipiFlow capital
• Specialty CLs -- sclerals + ortho-k + custom multifocals require fitting skill + topo + lab relationships
• Neuro-optometry / post-concussion -- emerging specialty (neurolens prism, vision therapy TBI, sports vision)
• Premium relationship care -- 45-min comprehensive exams + same-OD continuity; chains run 15-20 min slots
• Medical-OD chronic disease -- diabetic + glaucoma + dry eye + AMD at 2-3x vision-plan reimbursement

The 2027 surviving independent optometry practice is built deliberately for one of five end-states: (a) IDSO-equivalent partial-recap at 5-8x EBITDA + retained equity second-bite, (b) traditional sale at 60-85% collections, (c) merge with adjacent peer, (d) phased associate/family succession with real-estate retention, OR (e) multi-generational lifestyle independent. Practices drifting without exit clarity get under-valued OR forced into rushed sale to whichever chain/IDSO appears first.

The Operating Journey: From Solo Lane Cold-Start To Multi-Location + IDSO Exit

Sources

1. **American Optometric Association (AOA)** -- Annual Practice Survey + OD supply + benchmarks
2. **ARBO (Association of Regulatory Boards of Optometry)** -- state licensure + NBEO
3. **ASCO (Association of Schools and Colleges of Optometry)** -- ~23 ACOE-accredited schools + grad placement + debt
4. **NBEO (National Board of Examiners in Optometry)** -- Parts I/II/III
5. **AAO (American Academy of Optometry)** -- annual meeting + fellowship + research
6. **BLS Occupational Outlook 2024 -- Optometrists** -- supply + wages + employment
7. **Vision Council** -- US optical retail $50B+
8. **Review of Optometric Business (RoB)** -- practice benchmarks + chain market share
9. **Review of Optometry Magazine** -- clinical + practice CE
10. **Modern Optometry Magazine** -- practice mgmt + clinical
11. **Vision Monday** -- optical retail + chain + M&A news
12. **Brien Holden Vision Institute** -- global myopia prevalence research
13. **International Myopia Institute (IMI)** -- myopia mgmt consensus + axial length protocols
14. **EssilorLuxottica (NYSE: EL)** -- Francesco Milleri Chairman + Andrea Guerra CEO + LensCrafters+Pearle+Target Optical+Sunglass Hut+EyeMed+Essilor
15. **LensCrafters** -- ~840 stores EssilorLuxottica
16. **Pearle Vision** -- ~500 franchise + corporate
17. **National Vision Inc (NASDAQ: EYE)** -- Reade Fahs CEO + ~1,400 stores + America's Best ~900 + Eyeglass World ~125 + Walmart Vision sublease + Fred Meyer
18. **America's Best Contacts & Eyeglasses** -- ~900 stores
19. **MyEyeDr** -- KKR-backed 2019 + Sue Downes CEO + ~860 offices fastest-growing roll-up
20. **Walmart Vision Centers** -- ~3,000+ stores sublease ODs
21. **Costco Optical** -- ~580+ warehouses + employed ODs $130-$180K
22. **Warby Parker (NYSE: WRBY)** -- Neil Blumenthal + Dave Gilboa + ~270 stores + ecommerce
23. **Vision Source** -- Steven Eiss + Essilor-owned 2015 + ~3,000+ affiliated ODs + $750/mo
24. **IDOC** -- Dave Brown CEO + ~500 affiliate + ~$1,200/mo + IDOC Connection
25. **PECAA** -- ~1,500+ aligned ODs + buying group + advisory
26. **EyeCare Partners** -- Partners Group + FFL Partners + ~700+ OD+MD largest
27. **EyeSouth Partners** -- Shore Capital + ~300+ ophthalmology-heavy
28. **Keplr Vision** -- Greenbriar Equity + ~110+ practices independent-friendly
29. **US Eye** -- Kuvera + Aldine + ~75+ OD+MD
30. **Vision Innovation Partners (VIP)** -- Centre Lane Partners + ~80+
31. **Spectrum Vision Partners** -- PE-backed Northeast OD+MD
32. **VSP Vision Care** -- Mike Hamlin CEO + ~80M lives largest US vision insurance + Eyefinity OfficeMate + Marchon + ~30% share
33. **EyeMed Vision Care** -- Lukas Ruecker CEO + ~70M + EssilorLuxottica-owned
34. **Spectera / UnitedHealthcare Vision** -- ~25M UHG
35. **Davis Vision / MetLife Vision** -- ~20M
36. **Versant Health (Superior+Davis)** -- merged vision plan
37. **CooperVision (Cooper Companies NYSE: COO)** -- MiSight 1-day FDA + Biofinity + MyDay + Paragon CRT ortho-k
38. **Johnson & Johnson Vision** -- Acuvue Oasys 1-Day HydraLuxe + Vita + Moist + LipiFlow + LipiScan
39. **Alcon (NYSE: ALC)** -- DAILIES TOTAL1 + Air Optix HydraGlyde + Precision1
40. **Bausch + Lomb (NYSE: BLCO)** -- INFUSE + Biotrue ONEday + Ultra
41. **Hoya Vision Care** -- Hoya Free-Form + MiYOSMART myopia + Recharge AR
42. **Essilor (EssilorLuxottica)** -- Varilux + Crizal + Transitions + Eyezen + Stellest myopia + Independent Labs
43. **Younger Optics** -- US lens lab + Drivewear + NuPolar
44. **Shamir Insight** -- Autograph III + Glacier+ AR + Computer + Blue Zero
45. **Walman Optical** -- employee-owned wholesale lab
46. **IcareLabs** -- FL independent wholesale lab
47. **Marchon Eyewear** -- Calvin Klein + Lacoste + Nike + Ferragamo distribution
48. **Safilo Group** -- Carrera + Hugo Boss + Jimmy Choo + Marc Jacobs
49. **Marcolin** -- Tom Ford + Guess + Bally + Tod's distribution
50. **Kering Eyewear** -- Gucci + Saint Laurent + Cartier + Balenciaga
51. **Heidelberg Engineering** -- Spectralis OCT gold standard multimodal
52. **Carl Zeiss Meditec (XETRA: AFX)** -- Humphrey HFA3 + Cirrus 6000 OCT + IOLMaster 700
53. **Topcon Healthcare** -- TRC-NW8 + Maestro2 + CT-1 + CV-5000 + KR-800 + Aladdin
54. **Optos (Nikon)** -- California ultra-widefield 200deg + Daytona
55. **Optovue (Visionix)** -- iVue 80 OCT + AngioVue
56. **Nidek Inc** -- ARK-1s + NT-510 + RT-6100 + OPD-Scan
57. **Marco Ophthalmic** -- Reichert acquired + TRS-3100/5100/6100 + Equip ARK-510A
58. **Reichert Technologies** -- 7CR NCT + Ultramatic RX phoropter
59. **Haag-Streit** -- BQ-900 slit lamp gold + Octopus 900 visual field
60. **iCare USA** -- TA01i rebound tonometer pediatric-friendly
61. **Medmont International** -- E300 corneal topographer ortho-k + scleral
62. **Eaglet Eye** -- ESP scleral lens fitting profilometry
63. **Oculus** -- Pentacam Scheimpflug + Keratograph 5M dry eye
64. **Tomey USA** -- OA-2000 axial length biometer
65. **Canon Medical (USA)** -- CR-2/CR-2 Plus non-mydriatic retinal cameras
66. **Lombart Instruments** -- broadest optometry equipment distribution
67. **TearLab Corporation** -- osmolarity diagnostic gold
68. Quidel InflammaDry -- MMP-9 inflammation strip.
69. **Lumenis** -- OptiLight M22 IPL FDA dry eye
70. **NuLids System** -- at-home dry eye device
71. EyePromise / OmegaScan -- omega-3 nutraceutical.
72. AbbVie (NYSE: ABBV) -- Restasis + Eysuvis + Allergan eye care.
73. Sun Pharma -- Cequa cyclosporine.
74. Viatris -- Tyrvaya nasal spray.
75. **Bausch + Lomb -- Miebo** -- perfluorohexyloctane
76. **Eyenuk** -- FDA-cleared diabetic retinopathy AI EyeArt
77. **Notal Vision** -- ForeseeHome AMD home monitoring
78. **RetinAI** -- multi-pathology OCT AI
79. **AEYE Health** -- FDA-cleared autonomous DR
80. **Compulink** -- Advantage PMS legacy + cloud broad OD
81. **RevolutionEHR** -- cloud OD-specific PMS fastest-growing
82. **Crystal PM** -- independent OD-focused PMS
83. **Eyefinity OfficeMate + ExamWriter** -- VSP-owned deep VSP integration
84. Maximeyes by NextGen / My Vision Express / Acuity Logic / Uprise -- additional PMS options.
85. **Weave** -- patient comms text+voice+reviews fastest-growing eyecare
86. Solutionreach / NexHealth / Doctible / 4Patient Care -- recall + reactivation.
87. **BostonSight SCLERAL** -- scleral lens lab gold
88. Valley Contax / X-Cel Specialty / Visionary Optics / Essilor Custom Stable -- scleral + specialty CL labs.
89. **Visioneering Technologies** -- NaturalVue Multifocal myopia control
90. **Treehouse Eyes** -- myopia management franchise
91. Imprimis Pharmaceuticals / Pacific Compounding / Leiter's Pharmacy -- compounded atropine 0.05%.
92. **CareCredit (Synchrony NYSE: SYF)** -- dominant healthcare financing
93. Sunbit / Cherry / Alphaeon Credit / LendingPoint / Proceed Finance -- patient financing.
94. **Live Oak Bank Eyecare Lending** -- top SBA eyecare
95. **Bank of America Practice Solutions** -- largest non-SBA practice financier eyecare
96. First Citizens Practice Solutions -- was Square 1 strong eyecare book.
97. **Provide.com** -- was Lendeavor + expanded to eyecare 2022
98. Huntington Practice Finance / US Bank Practice Finance / TD Bank Healthcare -- additional eyecare lenders.
99. Marco Financial / Topcon Financial / US Bank Equipment Finance / Essilor Instruments -- equipment leasing.
100. Provident Healthcare Partners -- eyecare-specific M&A advisory + IDSO research.
101. ROI Corp (was Edgewood) -- eyecare practice transitions advisory.
102. Eyecare Practice Transitions / Williams Group / Practice Concepts -- practice broker advisory.
103. **FTC Eyeglass Rule** -- Rx released after refraction no charge
104. **FTC Contact Lens Rule** -- CL Rx released after fitting + 1-yr verification
105. HHS OCR HIPAA Privacy + Security + Breach Notification. https://www.hhs.gov/ocr
106. OSHA Bloodborne Pathogens 29 CFR 1910.1030. https://www.osha.gov/bloodborne-pathogens

Numbers & Benchmarks

1. Industry size & OD supply 2024-2026

2. Chain consolidation trajectory (RoB)

3. Top chains + IDSO equivalents

4. Capital + practice launch 2026

5. Exam-lane equipment cost by tier

6. Vision plan write-off vs medical-OD net

7. Myopia management ARR per pediatric (4-yr course)

8. Dry eye disease protocol pricing

9. OD salary by setting (AOA + BLS 2024)

10. IDSO vs traditional sale multiples eyecare 2024-2026

11. Exam volume per OD-day benchmarks (RoB + IDOC)

Counter-Case: When An Optometry Practice Is A Bad Bet

A serious founder must stress-test against conditions that make 2027 optometry brutal:

(1) Chain saturation kills exam volume. If LensCrafters + America's Best + MyEyeDr + Walmart + Costco all sit within 2 miles, CAC is 2-3x higher + capture lags 30-50%. Scout zip-level chain density before signing. Independents thrive in zips with 1-2 chains max + suburban density 25K+ HH + HHI $75K+ + pediatric or 45+ retiree demographics.

(2) Taking VSP at full panel and bleeding optical margin 40-60%. VSP ~30% market share is hard to skip but reflexive credentialing w/ VSP + EyeMed + Spectera + Davis + Versant + March compresses optical net to 18-25%. The fix: open w/ VSP + 1-2 zip-relevant plans MAX + aggressive medical-OD billing + dry eye + specialty CL + myopia mgmt OUT-of-vision-plan.

Drop EyeMed (lowest-paying, ties to chains) by year 2.

(3) Under-investing in OCT + topographer + biometer. Independents opening 2027 without OCT ($40-$80K) + topographer ($25-$45K) + axial length biometer ($45-$70K) cannot bill 92133/92134 medical OCT, cannot fit ortho-k/sclerals, cannot measure axial length for myopia per IMI. Result: forced into vision-plan-only competing with chains on price = loses. 2027 minimum: OCT + topographer + biometer + retinal camera = $200-$355K.

(4) Ignoring optical S-T-O-P and missing 30-50% of revenue. Optical = 55-70% of independent OD gross. Top closes 75-85% via Select-Talk-Offer-Position; bottom 30-40% hands patient paper Rx + sticker. Gap on same OD-hours = $500-$700K/yr on $1M practice.

Owners blame "patients shopping online" when actual cause is no optician training + no S-T-O-P + no financing + no 2nd-pair.

(5) Staffing wrong mix. Common mistake: 2 part-time licensed opticians at $42-$60K. Better: 1 licensed optician (legal cover + complex Rx) + 1-2 dedicated optical sales ($16-$24/hr + 4-8% commission, trained on S-T-O-P) + 2 cross-trained techs ($18-$28/hr pre-test + scribe). Optical sales role drives 30-50% revenue lift.

(6) Failing to credential medical carriers. New ODs credential vision plans only, skipping BCBS/Aetna/Cigna/UHC/Medicare = cannot bill 99213-99215 + 92133 + 92134 + 92250 + 92083 + G0117 under medical. Medical credentialing 60-120 days per carrier -- start 4-6 months pre-opening. Heavy-medical 35-50% net vs heavy-vision-plan 18-28%.

(7) Ortho-K without proper training = liability + microbial keratitis risk. Ortho-K is $4-$8K LTV but carries 1:2,000-1:10,000 MK risk per literature. ODs without training = malpractice + state board complaint. The fix: Vision By Design + IAOMC + Paragon CRT certification + ~100 hr CE + first 20 fits under mentor + meticulous hygiene education + 1-week + 1-month + quarterly follow-ups.

(8) Over-leveraging de novo = 18-30 mo cash burn. Cold-start $350-$800K capital + $40-$75K/mo overhead + 18-30 mo ramp = $500K-$1.4M total cash before profitability. Family/spousal bridge typical. Acquisition (0-6 mo ramp) preferable for risk-averse; SBA 7(a) $400K-$1.2M at 60-80% collections + reserve $40-$120K.

(9) Drifting without exit clarity. 50s-60s without exit plan = suboptimal valuation -- rushed sale 0.55-0.70x OR forced IDSO uncompetitive multiple OR sold to local MyEyeDr at chain valuation. Plan 5-10 yr in advance: IDSO 5-8x EBITDA + second-bite OR mini-multi-location 6-9x OR phased associate/family OR lifestyle independent.

(10) Losing your lead optician or associate OD mid-year. 1-OD + 1-lead-optician practices are fragile. Lead optician (S-T-O-P closer) leaves = optical capture collapses 30-50% for 3-6 months. Associate OD leaves = exam volume cliffs immediately.

Fix: 2 opticians minimum + above-market wage + commission + retention bonuses; associate OD vesting equity over 3-5 yr.

Honest verdict. Viable IF you (a) commit to S-T-O-P optical capture as #1 priority Day 1 -- licensed optician + trained optical sales + Select-Talk-Offer-Position + 2nd-pair + financing; (b) transition aggressively to medical-OD billing -- credential BCBS/Aetna/Cigna/UHC/Medicare + bill 99213-99215 + 92133/92134/92250/92083/G0117 + drop EyeMed year 2; (c) build myopia management as differentiating specialty -- biometer + ortho-k or MiSight + Stellest + atropine + pediatric marketing + $1,500-$3,500/yr packages; (d) build dry eye center as front door -- TearLab + LipiScan + optionally IPL OptiLight + $300-$3,000 protocol packages; (e) invest in diagnostic imaging at startup -- OCT + topographer + biometer + retinal camera + AI = 2027 minimum; (f) maintain HIPAA + OSHA + state OD board + optician licensure + FTC compliance documented; (g) track optical capture + medical-vs-vision mix + recall + show + production/OD-hour + myopia LTV; (h) understand chain/IDSO landscape early -- IDSO 5-8x EBITDA + second-bite OR mini-multi-location 6-9x OR phased family/associate OR lifestyle independent; (i) size working capital correctly for 18-30 mo de novo or 0-6 mo acquisition + spousal bridge.

Otherwise 2027 economics grind toward EssilorLuxottica + MyEyeDr + National Vision + Walmart + Warby Parker chain compression + vision-plan write-off bleed + S-T-O-P-workflow gap.

Related Pulse Entries

• [[q9683]] -- Dental practice (DSO consolidation + hygienist recruiting + case acceptance parallel)
• [[q9682]] -- Auto repair shop (state-licensed + tech recruiting parallel)
• [[q9681]] -- Real estate brokerage (state-licensed + recruiting parallel)
• [[q9680]] -- Funeral home (community-relationship parallel)
• [[q9679]] -- Bookkeeping firm (PE roll-up parallel)

Recently Added — Related

• [How do you start a physical therapy practice in 2027?](/knowledge/q9687)
• [How do you start an urgent care clinic in 2027?](/knowledge/q9686)